NUS Medicine Launches Ellen Siow Professorship in Neurosurgery to Propel Neuro-Oncology Research

Today marks a significant milestone in the fight against one of the most aggressive and fatal brain cancers with the announcement of the Ellen Siow Professorship in Neurosurgery at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine). This prestigious academic chair has been established to honor the legacy of Ellen Siow and her family’s unwavering dedication to advancing medical research, education, and philanthropy. The establishment of this professorship represents a crucial investment in the future of neuro-oncology, intending to spearhead breakthroughs in our understanding and treatment of glioblastoma multiforme (GBM), the most common and lethal primary brain malignancy affecting adults worldwide.

Glioblastoma is characterized by its highly infiltrative growth patterns and resistance to conventional therapies, resulting in a median survival time of approximately 15 months after diagnosis despite aggressive treatment. Existing therapeutic modalities, including surgical resection followed by radiation therapy and chemotherapy with temozolomide, offer limited success, underscoring the pressing need for translational research that bridges the gap between basic science and clinical applications. The Ellen Siow Professorship in Neurosurgery is engineered to facilitate such critical research endeavors, stimulating the discovery of novel therapeutic agents, personalized medicine approaches, and enhanced surgical techniques that can improve patient prognosis and quality of life.

The focus of this professorship centers particularly on brain tumors and gliomas, with an emphasis on neuro-oncology as an interdisciplinary field. Neuro-oncology integrates neurosurgical expertise, molecular biology, genetics, immunology, and advanced imaging technologies to understand tumor pathogenesis and progression better. Through funding the professorship, NUS Medicine will be empowered to appoint a leading expert in this area, thereby elevating Singapore’s position in global neuro-oncological research and clinical care innovation.

The origins of this endowment are deeply personal and profound. As recounted by Ms. Doreen Siow, a family representative, glioblastoma tragically affected her family twice over multiple generations. Her father succumbed to a brain tumor in 1963 during surgical intervention, and more recently, her sister Ellen was diagnosed with GBM in 2022 and passed away within six months despite surgical and medical management. These poignant experiences highlight the urgency and emotional impetus behind the family’s philanthropy. The funds allocated to establish this professorship come from the estate of Willie Siow Fung Wai Ying, the family matriarch, whose lifetime of philanthropy and commitment to community welfare embodied the spirit of giving and societal contribution.

Willie Siow’s charitable endeavors spanned healthcare, education, and elder care, demonstrating a holistic concern for welfare coupled with a belief in the transformative power of knowledge. Her endowment to NUS Medicine epitomizes this vision, channeling resources toward the acceleration of cutting-edge research that aims to extend survival and improve life quality for GBM patients. The decision to focus on glioblastoma as the target area for this professorship is rooted strongly in the reality that despite advances in other cancer therapies, effective treatment modalities for GBM remain frustratingly elusive due to the tumor’s molecular heterogeneity, invasive nature, and capacity to evade immune surveillance.

Glioblastomas originate from astrocytes, a type of glial cell providing critical support to neurons within the central nervous system. Their aggressive phenotype is marked by rapid proliferation, necrosis, neovascularization, and a unique ability to infiltrate adjacent healthy brain tissue, posing significant challenges for complete surgical resection. Moreover, the blood-brain barrier limits the penetration of many chemotherapeutic agents, complicating pharmacological interventions. Researchers at NUS intend to explore these challenges by advancing molecular profiling techniques, investigating tumor microenvironment interactions, and developing immunotherapeutic strategies that harness the patient’s own immune system to combat tumor cells.

Integrated clinical and academic research will be essential to driving tangible progress. The professorship will fortify NUS Medicine’s capacity to cultivate talent and expand neuro-oncological research programs, fostering collaborations with local hospitals and international research institutions. This integrative approach aligns with the translational research paradigm—moving innovations from bench to bedside with the ultimate aim of delivering improved diagnostic tools, targeted therapies, and potentially curative interventions.

Professor Chong Yap Seng, Dean of NUS Medicine and Lien Ying Chow Professor in Medicine, expressed deep gratitude toward the Siow family, emphasizing the transformative impact this professorship would have on neuro-oncology research and clinical practice in Singapore and the broader region. The professorship stands to invigorate ongoing research initiatives while attracting eminent scientists to lead pioneering studies on glioblastoma biology, treatment resistance, and patient-centered care pathways. This endeavor reflects a broader global movement within academic medicine to invest in specialty professorships to drive forward niche, high-impact medical research areas.

Understanding the molecular underpinnings of glioblastoma is at the frontier of current oncological research. Key genetic alterations, such as mutations in the p53 tumor suppressor gene, amplification of the epidermal growth factor receptor (EGFR), and dysregulation of signaling pathways like PI3K/Akt/mTOR, contribute to tumor survival and proliferation. The Ellen Siow Professorship will support work that elucidates these complex pathways further, seeking biomarkers for early detection and novel molecular targets that could be exploited therapeutically.

Beyond molecular biology, this professorship also seeks to advance innovations in surgical techniques and neuroimaging modalities. Technologies such as intraoperative MRI, fluorescence-guided resection, and precision radiotherapy are being refined globally, and their integration into clinical practice holds promise to enhance tumor removal while preserving neurological function. The professorship will facilitate research to optimize these technologies in the context of glioblastoma treatment, tailoring interventions to individual patient anatomy and tumor characteristics to maximize efficacy and safety.

As the morbidity and mortality associated with glioblastoma remain critically high, the psychosocial impact on patients and families is immense. The Ellen Siow Professorship intends not only to push boundaries in scientific discovery but also to promote holistic patient care models that address quality of life, symptom management, and palliative care approaches. This comprehensive focus ensures that research is patient-centered, balancing laboratory advancements with clinical realities.

The establishment of this professorship, funded through the philanthropy of the Siow family’s estate, embodies a powerful legacy of hope, resilience, and commitment to ending the grim prognosis of glioblastoma. By enabling sustained research investment and academic excellence, NUS Medicine positions itself as a leader in neuro-oncology and serves as a beacon for translational research that can ultimately improve survival outcomes and transform patient care paradigms for this devastating disease.

With the support of the Ellen Siow Professorship in Neurosurgery, Singapore takes a bold step forward in addressing a critical unmet need in cancer treatment. This visionary initiative represents the confluence of personal tragedy, scientific ambition, and societal responsibility. As research progresses, it is anticipated that new therapeutic paradigms will emerge, offering renewed hope to patients and families facing glioblastoma, not only in Singapore but globally.

News Publication Date: Not specified in the provided content

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/4a7837d2-818b-4531-a235-9fe6e12a7801/Rendition/low-res/Content/Public